Evidence map›Paper›PMID 27815444›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.

Yajing Chen, Richard Wilson, Sijy O'Dell, Javier Guenaga, Yu Feng, Karen Tran, Chi-I Chiang, Heather E Arendt, Joanne DeStefano, John R Mascola and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Yajing ChenDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0001-8330-3901
Richard WilsonInternational AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-7718-5344
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Javier GuenagaInternational AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0003-3912-7482
Yu FengInternational AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037.
Karen TranInternational AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-4393-2073
Chi-I ChiangInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
Heather E ArendtInternational AIDS Vaccine Initiative, Brooklyn, NY 11226; and.
Joanne DeStefanoInternational AIDS Vaccine Initiative, Brooklyn, NY 11226; and.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Richard T WyattDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037.
Yuxing LiDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037; liy@ibbr.umd.edu.
Scripps Research Institute · USInternational AIDS Vaccine Initiative · USNational Institutes of Health · USAdvanced Bioscience Laboratories (United States) · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AHMED, RAFI · 2012 to 2018
$131.5M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Non-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2014 to 2018
$14.6M
High-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6M
NIAID NIH HHS P01 AI104722NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI102766NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

Elicitation of broadly neutralizing Ab (bNAb) responses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary receptor CD4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished. However, a large number of CD4bs-directed bNAbs have been isolated from HIV-1-infected individuals. Comparison of the routes of binding used by the CD4bs-directed bNAbs from patients and the vaccine-elicited CD4bs-directed mAbs indicates that the latter fail to neutralize primary virus isolates because they approach the Env spike with a vertical angle and contact the specific surface residues occluded in the native spike, including the bridging sheet on gp120. To preferentially expose the CD4bs and direct the immune response away from the bridging sheet, resulting in an altered angle of approach, we engineered an immunogen consisting of gp120 core in complex with the prototypic CD4-induced Ab, 17b. This mAb directly contacts the bridging sheet but not the CD4bs. The complex was further stabilized by chemical crosslinking to prevent dissociation. Rabbits immunized with the crosslinked complex displayed earlier affinity maturation, achieving tier 1 virus neutralization compared with animals immunized with gp120 core alone. Immunization with the crosslinked complex induced transient Ab responses with binding specificity similar to the CD4bs-directed bNAbs. mAbs derived from complex-immunized rabbits displayed footprints on gp120 more distal from the bridging sheet as compared with previous vaccine-elicited CD4bs Abs, indicating that Env-Ab complexes effectively dampen immune responses to undesired immunodominant bridging sheet determinants.

Indexed as

AIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntigen-Antibody ComplexBinding SitesCD4 Antigensenv Gene Products, Human Immunodeficiency VirusEpitopesGlycosylationHIV-1HIV AntibodiesHIV Envelope Protein gp120ImmunizationModels, MolecularProtein BindingAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingAntigen-Antibody ComplexCD4 Antigensenv Gene Products, Human Immunodeficiency VirusEpitopesgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120

Identifiers

PMID27815444
PMCPMC5117957
OpenAlexW2531534301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.